Date:2/11/2008

gy industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward- looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

CONTACTS: James Winschel, Senior Vice President and Chief Financial

Officer

Jill Baker, Vice President of Investor Relations

+1-781-434-4118

'/>"/>

SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
2. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
3. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Cryo-Cell International, Inc. Reports Results for Fiscal 2007